CD2-targeted chimeric antigen receptor T-cell therapy

CD2-targeted chimeric antigen receptor (CAR) T-cell therapy is an investigational adoptive cellular immunotherapy designed to treat T-cell malignancies, such as T-cell acute lymphoblastic leukemia (T-ALL) and T-cell non-Hodgkin lymphoma (T-NHL). CD2 is a cell surface glycoprotein and adhesion molecule expressed on nearly all normal and malignant T cells and natural killer (NK) cells. The therapy involves engineering T cells to express a CAR that specifically recognizes the CD2 antigen, allowing the modified cells to identify and eliminate CD2-positive tumor cells. A major technical challenge in the development of CD2 CAR-T cells is "fratricide," a process where the CAR-T cells attack each other because they naturally express the CD2 target. To mitigate this, developers often employ gene-editing technologies, such as CRISPR/Cas9, to knock out the endogenous CD2 gene in the CAR-T cells. Clinical development is currently focused on early-phase trials evaluating safety and preliminary efficacy in patients with relapsed or refractory T-cell cancers.

Other names

CD2 CAR-TCD-2 CAR-TCD 2 CAR-TCD2-specific CAR-TCD-2-specific CAR-TCD 2-specific CAR-TCD2-directed CAR-T cell therapyCD-2-directed CAR-T cell therapyCD 2-directed CAR-T cell therapy